Postpartum Depression Treatment Market Report 2026

The postpartum depression treatment market size has grown strongly in recent years. It will grow from $1.28 billion in 2025 to $1.37 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing clinical recognition of postpartum depression, limited availability of specialized treatment options, reliance on conventional antidepressants, expansion of hospital-based mental health services, growing psychotherapy utilization.

The postpartum depression treatment market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing approval of novel postpartum therapeutics, rising investments in maternal mental health research, expansion of outpatient and home-based treatment models, growing demand for personalized medicine, increasing integration of digital therapeutics. Major trends in the forecast period include increasing adoption of combination therapy approaches, growing use of telepsychiatry for postpartum care, rising demand for rapid-acting antidepressants, expansion of hormone-based treatment options, enhanced focus on personalized treatment pathways.

The growing awareness of mental health issues during pregnancy is expected to drive the expansion of the postpartum depression treatment market in the coming years. Mental health issues during pregnancy encompass a range of emotional, psychological, and psychiatric conditions that may affect women while they are pregnant. The rise in these mental health concerns is largely attributed to increased stress levels and hormonal fluctuations, which heighten emotional vulnerability and make it more challenging for women to manage physical, social, and psychological demands. Postpartum depression treatment supports mental well-being by reducing symptoms such as sadness, anxiety, and fatigue, strengthening emotional resilience, and fostering healthier mother-child bonding. For instance, in October 2024, according to the Maternal Mental Health Leadership Alliance, a US-based nonprofit organization focused on improving maternal mental health, maternal mental health conditions are the most common complication of pregnancy, affecting approximately 800,000 families in the United States each year, with 75% of cases remaining untreated, posing long-term risks to mothers, infants, and families. Therefore, the increasing awareness of mental health issues during pregnancy is contributing to the growth of the postpartum depression treatment market.

Major companies operating in the postpartum depression treatment market are concentrating on advancements in diagnosis and therapy, including the development of prescription digital treatments, to improve patient outcomes and expand access to care. Prescription digital postpartum depression treatments refer to clinically validated digital therapeutics that are prescribed by healthcare providers to manage and treat postpartum depression. For instance, in April 2024, Curio Digital Therapeutics Inc., a US-based digital health company, received clearance from the US Food and Drug Administration for MamaLift Plus, the first prescription digital therapeutic for postpartum depression. This eight-week program delivers digital cognitive behavioral therapy, behavioral activation therapy, interpersonal therapy, and dialectical behavior therapy via a mobile device under healthcare provider supervision. A pivotal study demonstrated a significantly higher rate of clinically meaningful improvement in Edinburgh Postnatal Depression Scale scores among MamaLift Plus users compared to a control group. This regulatory clearance provides women with a non-pharmaceutical option for treating mild to moderate postpartum depression.

In July 2025, Supernus Pharmaceuticals, Inc., a US-based biopharmaceutical company focused on developing treatments for neuropsychiatric conditions, completed the acquisition of Sage Therapeutics, Inc. for an undisclosed amount. Through this acquisition, Supernus expanded its portfolio to include ZURZUVAE (zuranolone), an FDA-approved oral therapy for postpartum depression, and gained access to Sage’s innovative central nervous system discovery platform to support mid- to long-term revenue growth. Sage Therapeutics, Inc. is a US-based company engaged in the development of therapies for neurological and neuropsychiatric disorders, including depression, postpartum depression, and other mental health conditions.

Major companies operating in the postpartum depression treatment market are LifeStance Health Inc., Max Healthcare Institute Limited, American Well Corporation, Sakra Premium Hospital Private Limited, Talkspace Inc., Mental Health America, Seven Cups Inc., Marinus Pharmaceuticals Inc., Beyond Blue Ltd, Blooming Wellness Center, Sage Therapeutics Inc., Nurx Inc., Curio Digital Therapeutics Inc., Genesis Lifestyle Medicine, Postpartum Society Of Florida, TalktoAngel, The Motherhood Center, Otsuka Pharmaceutical Co Ltd, Lundbeck A S, Eli Lilly And Company, Pfizer Inc., Johnson And Johnson.

North America was the largest region in the postpartum depression treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the postpartum depression treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the postpartum depression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the postpartum depression treatment market by raising costs of imported pharmaceutical ingredients, specialty drugs, medical devices, and digital therapy platforms used in treatment delivery. North America and Europe are particularly impacted due to reliance on cross-border pharmaceutical supply chains, while Asia-Pacific faces cost pressures in drug manufacturing and distribution. These tariffs can increase treatment costs and delay access to advanced therapies. At the same time, they are encouraging domestic drug production, regional clinical research investments, and localized development of digital and therapeutic solutions for maternal mental health.

The postpartum depression treatment market research report is one of a series of new reports that provides postpartum depression treatment market statistics, including postpartum depression treatment industry global market size, regional shares, competitors with a postpartum depression treatment market share, detailed postpartum depression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the postpartum depression treatment industry. This postpartum depression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Postpartum depression (PPD) treatment involves the medical and psychological care provided to individuals who experience depression following childbirth. It generally includes a combination of therapeutic approaches, medications, and supportive strategies designed to relieve symptoms such as ongoing sadness, anxiety, fatigue, and difficulty bonding with the infant. These interventions may include pharmacological treatments, psychotherapy, hormonal therapy, and lifestyle modifications aimed at improving maternal mental health and overall well-being.

The primary categories of postpartum depression treatment include postpartum anxiety, postpartum blues, postpartum post-traumatic stress disorder (PTSD), postpartum obsessive-compulsive disorder (OCD), postpartum panic disorder, and postpartum psychosis. Postpartum anxiety is characterized by excessive worry, fear, or nervousness in new mothers after delivery. Treatment options such as antidepressants, hormone therapy, psychotherapy, and others are available for different age groups, including adolescents and adults. These treatments are supplied through multiple distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The postpartum depression treatment market consists of revenues earned by entities by providing services such as psychotherapy, medication management, counseling, digital mental health solutions, and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The postpartum depression treatment market also includes sales of antidepressant medications, hormone-based therapies, digital health platforms, telehealth services, wearable devices, and mobile applications that support mental health management. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.